AU759273B2 - Use of retinal pigment epithelial cells for creation of an immune privilege site - Google Patents

Use of retinal pigment epithelial cells for creation of an immune privilege site Download PDF

Info

Publication number
AU759273B2
AU759273B2 AU20191/99A AU2019199A AU759273B2 AU 759273 B2 AU759273 B2 AU 759273B2 AU 20191/99 A AU20191/99 A AU 20191/99A AU 2019199 A AU2019199 A AU 2019199A AU 759273 B2 AU759273 B2 AU 759273B2
Authority
AU
Australia
Prior art keywords
cells
rpe
population
cell population
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU20191/99A
Other languages
English (en)
Other versions
AU2019199A (en
Inventor
Richard C. Allen
Michael L. Cornfeldt
William R Kidwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Titan Pharmaceuticals Inc
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Publication of AU2019199A publication Critical patent/AU2019199A/en
Application granted granted Critical
Publication of AU759273B2 publication Critical patent/AU759273B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
AU20191/99A 1998-01-02 1998-12-31 Use of retinal pigment epithelial cells for creation of an immune privilege site Ceased AU759273B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US241398A 1998-01-02 1998-01-02
US09/002413 1998-01-02
PCT/US1998/027730 WO1999034834A1 (en) 1998-01-02 1998-12-31 Use of pigmented retinal epithelial cells for creation of an immune privilege site

Publications (2)

Publication Number Publication Date
AU2019199A AU2019199A (en) 1999-07-26
AU759273B2 true AU759273B2 (en) 2003-04-10

Family

ID=21700636

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20191/99A Ceased AU759273B2 (en) 1998-01-02 1998-12-31 Use of retinal pigment epithelial cells for creation of an immune privilege site

Country Status (8)

Country Link
US (1) US20060147437A1 (enExample)
EP (1) EP1044024A1 (enExample)
JP (1) JP2002500202A (enExample)
KR (1) KR20010033834A (enExample)
AU (1) AU759273B2 (enExample)
CA (1) CA2317115A1 (enExample)
NZ (1) NZ505459A (enExample)
WO (1) WO1999034834A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
JP2002281964A (ja) * 2000-12-26 2002-10-02 Sanyo Chem Ind Ltd 細胞生産方法
WO2002066620A2 (de) * 2001-02-21 2002-08-29 Stefan Kochanek Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
WO2003092723A1 (de) * 2002-05-03 2003-11-13 Nikolai Rainov Verwendung von fasl zur behandlung von neurodegenerativen erkrankungen
EP1551956A4 (en) 2002-07-12 2006-12-27 Univ Washington METHOD AND SYSTEMS FOR THE EXTENDED IN VITRO CULTURE OF NEURONAL CELLS
US20040156878A1 (en) * 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
CA2937099A1 (en) * 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2209888B1 (en) 2007-10-12 2019-12-04 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212082A (en) * 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
EP0673259A4 (en) * 1992-01-23 1995-12-06 Univ New York METHOD FOR TRANSPLANTING CELLS INTO THE BRAIN AND THERAPEUTIC USE THEREOF.
JP3490447B2 (ja) * 1993-04-30 2004-01-26 フォトジェネシス インコーポレイテッド 網膜色素上皮移植
AU715177B2 (en) * 1994-04-13 2000-01-20 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells and allografts or xenografts
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURRENT EYE RESEARCH VOL 12, P 629-639 1993 *

Also Published As

Publication number Publication date
EP1044024A1 (en) 2000-10-18
JP2002500202A (ja) 2002-01-08
KR20010033834A (ko) 2001-04-25
CA2317115A1 (en) 1999-07-15
AU2019199A (en) 1999-07-26
NZ505459A (en) 2003-07-25
WO1999034834A1 (en) 1999-07-15
US20060147437A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US7115257B1 (en) ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP4950659B2 (ja) 胎盤組織から由来最多分娩後細胞、及びそれらを作成し使用する方法。
US6255112B1 (en) Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
US20060147437A1 (en) Use of pigmented retinal epithelial cells for creation of an immune privilege site
KR102510368B1 (ko) 혈관 콜로니 형성 세포
JP7027026B2 (ja) 眼疾患を処置するためのａｂｃｂ５（＋）幹細胞
US20030125293A1 (en) Adipose tissue-derived stromal cells for the repair of corneal and intra-orbital defects and uses thereof
JP2005524633A (ja) 増殖した細胞系およびその使用方法
CA2131305A1 (en) Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
KR20070001108A (ko) 각막 윤부로부터 유도된 미분화 줄기 세포를 가진 조직시스템
KR20080097226A (ko) 결막 조직 시스템
JP4543036B2 (ja) 皮膚再生システム
Li et al. Human adipose-derived stem cells delay retinal degeneration in royal college of surgeons rats through anti-apoptotic and VEGF-mediated neuroprotective effects
CA2450650C (en) Encapsulated cell therapy
US20090269319A1 (en) ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
JP2008520215A (ja) 骨髄幹細胞からインビトロで分化した網膜特異的細胞、その産生およびその使用
CN111417718A (zh) 由cd31阳性cd45阴性cd200阳性的哺乳动物细胞组成的细胞群及其应用
Oda et al. A simple method for the Schwann cell preparation from newborn rat sciatic nerves
Ho et al. Tissue culture of retinal pigment epithelium following isolation with a gelatin matrix technique
MXPA00006546A (en) Use of pigmented retinal epithelial cells for creation of an immune privilege site
US20160058796A1 (en) Retina extracellular matrix based biomaterial
WO2006116678A2 (en) Tissue targeting of stem cells
US12226452B2 (en) Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
EP4176870A1 (en) Extracellular vesicles or composition thereof for use as a medicament, such as for the treatment of ocular surface disorders
Mitrousis A Bioengineering Approach Towards Retina Regeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)